Spero Therapeutics Inc. (SPRO)
Symbol Info
Listed Symbol SPRO
Name Spero Therapeutics Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $3,966,000
Latest Fiscal EPS $-2.62
Price Info
21 Day Moving Average $10.7819
21 Day EMA $10.818540
50 Day Moving Average $10.6205
50 Day EMA $10.779430
200 Day EMA $10.852830
200 Day Moving Average 11.052930
52 Week High $14.48
52 Week Low $5.52
52 Week Change $25.834799
Alpha 0.084637
Beta 2.1858
Standard Deviation 0.423200
R2 0.041934
Periods 38
Share Information
10 Day Average Volume 41,639
20 Day Average Volume 38,951
30 Day Average Volume 49,600
50 Day Average Volume 40,759
Outstanding Shares 18,656,200
Float Shares 18,557,248
Percent Float 99.47%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 131
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 1,273,890
Institute Holdings Percent 61.800000
Institute Sold Previous 3 Months 508,146
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned 98,952
Price Change
7 Day Price Change $-0.29
7 Day Percent Change -2.63%
21 Day Price Change $-0.1599999
21 Day Percent Change -1.47%
30 Day Price Change $-1.29
30 Day Percent Change -10.72%
Month To Date Price Change $0.1400
Month To Date Percent 1.32%
90 Day Price Change $0.530000
90 Day Percent Change 5.19%
Quarter To Date $0.139999
Quarter To Date Percent 1.32%
180 Day Price Change $-1.110001
180 Day Percent Change -9.37%
200 Day Price Change $-2.45
200 Day Percent Change -18.57%
Year To Date $4.590000
Year To Date Percent 74.63%
Profile
Description Spero Therapeutics Inc is a US-based clinical-stage biopharmaceutical company. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections. The company's product candidate, SPR994, is designed as a broad-spectrum oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It has developed platform technology known as Potentiator Platform to develop drugs to expand the spectrum and potency of existing antibiotics, including formerly inactive antibiotics, against Gram-negative bacteria. In addition, the company is developing SPR720, an oral antibiotic designed for the treatment of pulmonary non-tuberculous mycobacterial infections. The pipeline products include SPR741, SPR206, and SPR720.
Details
Issue Type CS
Market Cap $200,367,588
Sec Type
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 18,656,200
CEO Ankit Mahadevia
Employees 41
Last Audit UE
Classification
CIK 0001701108
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 675 Massachusetts Avenue
14th Floor
Cambridge, MA 2139
Website https://www.sperotherapeutics.com/
Facisimile
Telephone +1 857 242-1600
Email IR@sperotherapeutics.com
Key Ratios
Profitability
EBIT Margin -338.4
EBITDA Margin -333.6
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $11,566,000
Revenue Per Share $0.6200
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $103,860,770
Price To Sales 17.323845
Price To Free Cash -5.2
PE High Last 5 Years -
Price To Book 1.9
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 1.9
Financial Strength
Total Debt To Equity 0.0
Int Coverage -
Current Ratio 13.7
Leverage Ratio 1.1
Quick Ratio 12.9
Long Term Debt To Capital 0.04
Assets
Receivables Turnover 1.8
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -40.27
Return On Equity -44.99
Return On Capital -44.88
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
SPRO
Spero Ther..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.